CB Therapeutics Inc. has developed an innovative and proprietary cellular agriculture platform to efficiently research, discover, develop and produce therapeutic compounds to advance neuroscience.
The company's initial focus is on producing cannabinoids for use in nutraceuticals, topical treatments, cosmetics, food and beverage and animal healthcare. In its 7,000 sq. ft. fully-licensed commercial batch facility in Southern California, it produces and sells CBC, CBG and CBT with plans to move into CBN, CBDA, CBGA, CBCA, CBD, THCV and THCVA cannabinoid compounds.
More recently, CB Therapeutics has focused on developing tryptamines, such as psilocybin, DMT and their analogs for use in accredited clinical trials for the treatment of depression, PTSD, anxiety, addiction and other mental disorders. The company's Schedule 1 license with the U.S. DEA could open the door to these production efforts and create a barrier to entry for competitors.
The company has also built a bioinformatics platform designed to filter and discover unique and optimal enzymes from plants and other sources that it scales using yeasts, enzymes and other production processes that scale faster than they do nature.
Sher Ali Butt
Co-Founder & CEO
Co-Founder & CSO
VP of Operations